Posts

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

on

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

on

Sarepta Reports Death of DMD Patient Following Elevidys Gene Therapy Treatment

on

Orca's cell therapy trounces traditional care in blood cancer phase 3, swimming into space's 'holy grail'

on

Kura Oncology and Kyowa Kirin Report Positive Phase 2 Results for Ziftomenib in AML, Prepare for FDA Submission

on

Kura Oncology's Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program

on

FDA Approves Axsome's Symbravo for Acute Migraine Treatment, Overcoming 2022 Rejection

on

FDA Approves Axsome's Symbravo for Rapid Migraine Relief

on